Quest, PeaceHealth agreement, 6/17
June 2017—Quest Diagnostics and PeaceHealth have formed a two-part arrangement to enhance the delivery of laboratory services to communities in Oregon, Washington, and Alaska.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
NGS cancer panels, 6/17
June 2017—Oxford Gene Technology has expanded its SureSeq myPanel NGS Custom Cancer Panel content. The expanded content covers more than 70 genes optimized for hematology and solid tumors including breast, colorectal, lung, ovarian and prostate cancer, glioma, melanoma, sarcoma, leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome.
Deep learning AI analytics platform, 6/17
June 2017—Fimmic launched its next-generation WebMicroscope Deep Learning Platform. Fimmic’s cloud platform brings deep learning artificial-intelligence-based image analysis to pathologists and researchers, no matter the size of a project.
FDA-cleared next-gen troponin T test, 6/17
June 2017—Roche received 510(k) clearance for its Elecsys Troponin T Gen 5 STAT blood test for patients with a suspected heart attack. With this clearance, according to a company statement, Roche is the first IVD company in the U.S. to provide next-generation troponin testing for patients as an aid in the diagnosis of myocardial infarction, enabling clinicians to more accurately identify patients experiencing a heart attack.
Pan-ethnic solution for carrier status research, 6/17
June 2017—Thermo Fisher Scientific released its CarrierScan Assay, a high-throughput, microarray-based assay that provides molecular genetics laboratories with a consolidated and automated single pan-ethnic solution for expanded carrier status research.
Multiplexed analysis to detect gene fusions, 5/17
May 2017—Agena Bioscience announced a comparative study published in Scientific Reports highlighting the use of its mass-spec-based platform for transcriptome analysis of ALK, ROS1, and RET gene fusions in lung cancer.
Monoclonal antibodies to Shigella, 5/17
May 2017—ViroStat released two sets of monoclonal antibodies to Shigella—one set specific to Shigella sonnei and another set specific to Shigella flexneri 2a. Potential applications for these include direct bacterial detection by ELISA and lateral flow rapid tests.
Molecular flu tests cleared, 5/17
May 2017—Cepheid received FDA clearance to market Xpert Xpress Flu and Xpert Xpress Flu/RSV. Both tests deliver reference-quality molecular results in as little as 20 minutes. The tests are Cepheid’s first Xpress branded products, which are expected to deliver results in 30 minutes or less.
BD Veritor meets new FDA flu requirements, 5/17
May 2017—Becton Dickinson announced that its BD Veritor System Flu A+B, a digital immunoassay for the rapid detection of influenza, meets the new FDA performance requirements in which antigen-based rapid influenza virus antigen detection systems (RIDTs) intended to detect influenza virus directly from clinical specimens have been reclassified from class I devices to class II devices subject to special controls.
ROS1, RET mutations added to liquid biopsy test, 5/17
May 2017—Biodesix announced that its GeneStrat test, a liquid biopsy for patients with cancer, now includes ROS1 and RET. GeneStrat is a noninvasive blood test analyzing circulating tumor DNA and RNA. The test provides highly sensitive results in 72 hours for non-small cell lung cancer patients.